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Exposure to lead constitutes a serious occu-
pational and environmental health problem
(1-3). At high exposure levels, lead has
been demonstrated to cause encephalopa-
thy (4,5), kidney damage (6-9), anemia
(2), and toxicity to the reproductive system
(10,11). Lead exposure may also lead to
elevated rates of hypertension (12-14). At
lower doses, lead has been associated with
alterations in cognitive development in
children (14-154 The nature and degree of
the health risks posed by exposures to low
levels oflead are a matter ofdebate but, to
date, unequivocally safe exposure levels
have not been identified (1).
The health risks associated with low-
level exposures to lead have important
implications with respect to its regulation.
Standards and health-based guidelines lim-
iting occupational and environmental
exposures to lead have become more strin-
gent over the past decade and are now
thought to protect against major adverse
outcomes. However, as is the case with
most toxins, the low-dose risks posed by
lead are likely to be determined, in part, by
individual determinants ofsusceptibility. A
failure to adequately consider these factors
in the establishment of regulatory stan-
dards may result in the unacknowledged
imposition of substantial risks on some
members ofsociety.
Recent work has implicated a genetic
trait as a possible determinant of suscepti-
bility to higher blood lead levels. A rela-
tively common variant of the second
enzyme in heme biosynthesis, 6-aminole-
vulinic acid dehydratase (ALAD) has been
reported to be associated with susceptibili-
ty to higher blood lead concentrations
among children and workers (20-23). The
association of this variant, designated
ALAD-2, with elevated blood lead levels
was observed in populations exposed to
lead at relatively high levels; blood lead
concentrations in the three reported stud-
ies investigating this issue were generally in
excess of 10 pg Pb/dl (20-23).
The ALAD-2 allele is found in approx-
imately 11-20% ofwhites (24,25) and has
been postulated to act as a modifier of the
pharmacokinetics and toxicity oflead (20).
Although the precise mechanism involved
in the biological action of this genotype is
unknown, it may enhance the uptake,
decrease the elimination, and/or modify
the tissue distribution of lead in the body
perhaps due to an increased affinity of the
variant protein for lead. This possibility
follows from the observation that ALAD is
strongly inhibited by lead, which is
thought to exert this effect by displacing
zinc from the enzyme (26,27). Depending
on the target organ, such pharmacokinetic
effects could either enhance or reduce the
ultimate toxicity oflead.
To further investigate possible alter-
ations in lead kinetics associated with
ALAD genotype, we have studied mem-
bers of a construction trade union. In this
population, lead exposure may occur dur-
ing job-related activities such as the demo-
lition and renovation ofold buildings con-
taining lead paint and work using lead-
based solder, for example. This group was
expected to have relatively modest overall
exposures to lead, allowing for the poten-
tial impacts ofALAD-2 on lead body bur-
dens to be considered at levels more repre-
sentative of exposures occurring among
the population at large. We determined
ALAD genotype, blood lead concentra-
tions, and bone lead concentrations in
both the patella and tibia. Relationships
between genotype and blood pressure and
kidney function, endpoints that have pre-
viously been demonstrated to be adversely
affected bylead, were also investigated.
Methods
Volunteers were recruited at the 1991
International Brotherhood of Carpenters
and Joiners convention in Atlantic City,
New Jersey. Participants completed a
detailed questionnaire covering demo-
graphic, lifestyle, and occupational histories
and were screened for various medical con-
ditions including hypertension. Blood sam-
ples were voluntarily donated for determi-
nation of blood lead levels and ALAD
genotype. No exclusion criteria were
applied. This research was approved by the
Human Subjects and Research Committee
ofthe Brigham andWomens Hospital.
Lead determinations were made by
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Hoffman-LaRoche Laboratories using
anodic stripping voltametry (ESA model
3010). Eight percent ofthe samples consist-
ed of references obtained from the New
York Department of Health and were ana-
lyzed blind. The coefficients ofvariation for
blood lead determinations from this labora-
tory have been estimated as 10, 8, and
5-6% at blood lead concentrations of 1-10,
10-30, and 30-60 pg/dl, respectively.
For genotyping we used a polymerase
chain reaction (PCR)-based technique that
allows ALAD-1 and ALAD-2 alleles to be
rapidly differentiated from small samples
ofwhole blood (28). Briefly, amplifications
were performed essentially as described
(21) on 0.5 pl of whole blood using two
sets ofprimers specific for a portion ofthe
ALAD gene. Primer sequences for the ini-
tial round of amplification were
(5'-AGACAGACATTAGCTCAGTA-3')
and (5'-GGCAAAGAACACGTCCAT-
TC-3'), which generate a 916 base pair
fragment. To increase the amplification
yield, which was inconsistent from this
first amplification step when using whole
blood, a second round ofamplification was
performed using a nested pair of primers
(5'-CAGAGCTGTTCCACAGTGGA-3')
and (5'-CCAGCACAATGTGGGAGT-
GA-3') which generate a 887 base pair
fragment. Amplified DNA was then
restricted using MSPI and electrophoresed
through 2.0% agarose. ALAD alleles are
differentiated based on the existence of a
MSPI endonuclease restriction site specific
to the ALAD-2-derived PCR fragment,
which yields a diagnostic restriction band.
Heterozygotes exhibit both the ALAD-1
and ALAD-2 fragments and can thus be
differentiated from homozygotes of either
type. We performed PCR reactions in
duplicate with blank controls included in
each set.
Patella and tibia bone lead determina-
tions were made on a subset ofthose partici-
pating using a prototype ABIOMED K-
XFR instrument as described previously
(29). Briefly, this instrument uses a 109Cdy-
ray source to provoke the emission offluo-
rescent photons from target tissues. By esti-
mating counts derived from both lead and
bone matrix, a measurement in units of
micrograms lead per gram bone mineral is
derived. The uncertainty in the measure-
ment increases with thicker overlying tissue
and lower bone density. For this data set
estimates ofmeasurement uncertainty, based
on the strength ofthe returning signal, were
obtained for each individual, yielding an
overall uncertainty of7.0 ± 1.4 and 8.0 ± 1.6
pg/gfor the tibiaandpatella, respectively.
At very low bone lead concentrations,
the K-XFR instrument may generate nega-
tive point estimates ofbone lead, especially
if the associated measurement uncertainty
is large. These negative values are, howev-
er, informative as they become more likely
at lower bone lead concentrations. Thus,
negative values were retained in the analy-
ses. A complete discussion ofthis approach
is reviewed in Hu et al. (30).
We analyzed relationships between
genotypic status and blood and bone lead
concentrations as well as blood pressure
and three markers of kidney function
using Student's t-test, multivariate logis-
tic regression, and Wilcoxon-rank sum
methods. Because lead partitioning to
trabecular bone (here represented by the
patella) is quite distinct from partitioning
to cortical bone (here represented by the
tibia) (31,32), we also examined the
influence of ALAD status on the differ-
ence between tibia and patella bone lead
concentrations (i.e., the cortical-trabecu-
lar bone lead differential).
Results
Demographic characteristics of the study
population are presented in Table 1.
Volunteers were predominantly white
males with an average age of 48 years.
Blood lead values and ALAD genotypes
were obtained for 691 individuals. Bone
lead determinations were obtained on a
subset of 131 individuals from this larger
group; time constraints did not allow for
the testing of additional volunteers. Nine
people either did not adequately complete
the questionnaire (n = 4) or were not geno-
typed because blood samples were not
available (n = 5), leaving a total of 122
individuals for analysis.
Figure 1 presents a representative
ethidium-bromide stained gel displaying
the distinguishing restriction fragments
used to identify ALAD genotypes. A total
of594 ALAD 1-1 homozygotes (85.96%),
95 ALAD 1-2 heterozygotes (13.74%) and
2 ALAD 2-2 homozygotes (0.29%) were
identified. In further analyses the ALAD 1-
2 heterozygotes and 2-2 homozygotes have
been combined to generate a single catego-
ry of individuals carrying at least one
ALAD-2 allele. Although ALAD gene
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Figure 1. Polymerase chain reaction-based deter-
mination of ALAD genotype. ALAD 1-1 homozy-
gotes are characterized by a single 556 base pair
MSPI fragment (e.g., lane 2), ALAD 2-2 homozy-
gotes by a single 494 base pair fragment (e.g.,
lane 3), and heterozygotes contain both (e.g., lane
4). Lane 1 contains molecular weight standards
(MSPI digested pBR322), and lane 5 is the control.
dosage effects on lead pharmacokinetics
may be possible, the limited number of
AIAD 2-2 homozygotes identified in this
population preclude any meaningful analy-
sis ofthis possibility.
Blood lead values in this population
were relatively low, as expected, averaging
7.78 (± 3.60) pg Pb/dl. Average blood lead
concentrations were essentially identical
between ALAD genotypes (7.78 ± 3.62 ver-
sus 7.73 ± 3.48 pg Pb/dl for ALAD-1 and
ALAD-2, respectively; p = 0.73) (Table 2).
Plots of the cumulative frequency distrib-
ution of blood lead values by genotype
also revealed no apparent differences
across the blood lead concentration range
observed in this population (data not
shown).
Overall, bone lead concentrations were
relatively low in this population (9.43 ±
8.93 and 13.82 ± 11.77 pg Pb/g bone
mineral for tibia and patella, respectively)
(Table 2). Both tibia and patella bone lead
concentrations were significantly correlated
with age (p = 0.001).
Age-adjusted bone lead values, using
residuals of least-square regression, were
used to compare bone lead concentrations
between genotypes quantitatively. Age-
adjusted tibia values were somewhat higher
and patella values were lower in the ALAD-
1 group. Overall, average age-adjusted tibia
Table 1. Demographic characteristics ofthe study populationa
Characteristic Total ALAD-1/1 b ALAD-1/2 and -2/2c
Complete cohort
N 691 594 97
Age 48.1 ± 8.8 48.0 ± 8.8 49.2 ± 8.9
Alcohol (drinks/day) 0.2 ± 0.7 0.2 ± 0.7 0.1 ± 0.6
Smoking (cigarettes/day) 17.1 ± 15.6 17.3 ± 15.7 16.3 ± 14.9
Subgroup with bone lead determinations
N 122 101 21
Age 48.3 ± 9.9 48.2 ± 10.1 49.2 ± 8.9
Alcohol (drinks/day) 0.9 ± 1.4 1.0 ± 1.4 0.6 ± 1.2
Smoking (cigarettes/day) 16.0 ± 15.4 15.8 ± 15.6 16.9 ± 14.5
'Values are means ± SD.
bALAD 1/1, homozygous wild type.
CALAD 1/2 and2/2, heterozygous and homozygous variantforALAD-2 allele.
Volume 103, Number3, March 1995 249lead concentrations were 7.50 (± 7.70) pg
Pb/g bone mineral among the combined
ALAD-2 heterozygote/homozygote group
versus 9.87 (± 8.16) pg/g among those
homozygous for ALAD-1 (p = 0.29). In
contrast, ALAD-2 age-adjusted patella lead
values were higher: 15.98 (± 6.47) pg/g
compared to 13.37 (± 12.57) pg/g among
ALAD-1 homozygotes (p = 0.10).
Possible genotypic effects on the rela-
tive distribution of lead between the tibia
and patella (cortical versus trabecular bone
types) was investigated by subtracting the
measured lead concentrations in patella
bone from those observed in tibia bone for
each individual. The resulting population
mean values were 3.35 (± 11.99) and 8.62
(± 9.47) pg Pb/g bone mineral, forALAD-
1 and ALAD-2, respectively. This differ-
ence was of borderline statistical signifi-
cance (p = 0.06).
Population mean systolic and diastolic
blood pressures were not significantly ele-
vated among ALAD-2 individuals (Table
3). Comparisons ofthe number ofindivid-
uals expressing systolic blood pressure
above 140 and diastolic blood pressure
above 90 showed no significant association
with ALAD genotype (not shown).
Blood urea nitrogen (BUN), uric acid,
and creatinine were all elevated among
ALAD-2 individuals (Table 3). The differ-
ence in BUN values between genotypes
was statistically significant (p = 0.03),
while those for uric acid and creatinine
were of borderline significance (p = 0.07
andp = 0.10, respectively).
Potential relationships between BUN,
uric acid, and creatinine levels with
ALAD genotype were investigated further
using logistic regression models incorpo-
rating the additional variables of age,
blood lead concentration, and alcohol
consumption, factors potentially related
to kidney function. Table 4 presents para-
meter estimates, standard errors, and p-
values for the various models. Initially, all
variables (including genotypic status)
were included as independent variables.
Variables were dropped until only those
with p-values of less than 0.20 remained.
Values for these final models are present-
ed in Table 4.
Interestingly, blood lead concentrations
alone significantly predicted BUN out-
comes even at these low lead levels, with
ALAD genotypic status also being of bor-
derline statistical significance as an
explanatory variable (p = 0.06). For all
logistic models, ALAD status yielded the
highest parameter estimates and, in the
case ofuric acid, was also ofnear statistical
significance as an explanatory variable (p =
0.07). In this latter case, ALAD genotype
was the only variable that approached sta-
tistical significance.
Discussion
Inhibition ofALAD enzymatic activity is a
sensitive indicator of exposure to lead,
exhibiting a dose-response relationship
over a broad range of blood lead concen-
trations (26). This inhibition may be due
to the binding oflead to the enzyme, with
displacement ofthe normal metallic cofac-
tor, zinc (27). Astrin et al. (20) previously
reported a statistically significant overrep-
resentation ofthe ALAD-2 isozyme among
individuals with blood lead concentrations
in excess of 30 pg/dl compared to those
with levels below 20 pg/dl (20). A follow-
up study by Wetmur et al. (22) confirmed
this observation. In a smaller study of202
occupationally exposed workers, individu-
als carrying ALAD-2 also expressed higher
blood lead levels than ALAD 1-1 homozy-
gotes (23). Based on these observations, it
has been suggested that the ALAD-2 form
ofthe enzyme mayexhibit a greater affinity
for lead, increasing the overall uptake and
retention of lead in the body. Increased
susceptibility to the toxic effects of lead
have also been postulated, although no
investigations to date have explicitly
addressed this issue.
Previous studies focused on popula-
tions with relatively high exposures to lead;
although large cohorts were involved, few
individuals had blood lead levels below 10
pg/dl. Thus, these investigations did not
allow for a careful consideration ofpoten-
tial genotypic associations with lower
blood lead levels. Additionally, interpreta-
tion of the Astrin and Wetmur studies is
complicated by the fact that enrollment
into these investigations was based, in large
part, on initial clinical evaluations of ele-
vated erythrocyte protoporphyrin (FEP)
levels (20,22). This introduces a potential-
ly serious selection bias in the study design.
For example, ifALAD-2 reduced sensitivi-
ty to lead-induced FEP elevation, higher
blood lead levels would be required for this
genotype to be "captured" by the study,
leading to a spurious association of geno-
Table2. Blood and bone lead concentrations by6-aminolevulinic acid dehydratase (ALAD)genotype'
Genotype
Total population ALAD-1 ALAD-1/2 and -2/2 pb
All carpenters
N 688 592 96c
Blood lead level (pg/dl) 7.8 ± 3.6 7.8 ± 3.6 7.7 ± 3.5 0.89
Bone lead subcohort
N 122 101 21
Patella 13.7 ± 13.4 13.1 ± 14.1 16.4 ± 9.2 0.18
Tibia 9.4 ± 8.9 9.8 ± 9.1 7.8 ± 8.1 0.36
Adjusted patella 13.8 ± 11.8 13.4 ± 12.6 16.0 ±6.5 0.17
Adjusted tibia 9.5 ± 8.1 9.9 ± 8.2 7.5 ± 7.7 0.22
Blood lead level (pg/dl) 8.0 ± 3.9 8.0 ± 4.1 8.2 ± 3.2 0.85
Patella-tibia difference 4.3±11.7 3.4±12.0 8.6± 9.5 0.06c
aValues are means ± SD.
bWilcoxon and rank sum analysis, Kruskal-Wallis chi-square approximation, unless noted otherwise.
CALAD 1-2, N= 94; ALAD 2-2, N= 2.
dt-test.
Table 3. Markers of kidneyfunction and blood pressure levels bygenotypea
Genotype
Marker ALAD-1 ALAD-1/2 and -2/2 p
Blood urea nitrogen (mg/dl) 18.5 ± 4.6 19.6 ± 4.5 0.03
Uric acid (mg/dl) 6.4± 1.4 6.7± 1.6 0.07
Creatinine (mg/dl) 1.2 ± 0.2 1.3 ± 0.2 0.11
Diastolic blood pressure 84.1 ± 9.1 85.5 ± 9.2 0.16
Systolic blood pressure 133.5 ± 17.5 134.9 ± 15.0 0.47
ALAD, 8-aminolevulinic acid dehydratase.
aValues are means ± SD.
Table 4. Summary of logistic regression model for markers of kidneyfunction
BUN Uric acid Creatinine
Model variables Estimate p Estimate p Estimate p
ALAD statusa 0.91 0.06 0.28 0.09 0.03 0.16
Blood lead level (pg/dl) 0.13 0.005 0.002 0.91 0.001 0.50
Age (years) 0.12 0.0001 0.002 0.77 0.002 0.009
Alcohol consumption -0.04 0.87 0.13 0.12 0.003 0.77
(drinks/day)
Abbreviations: ALAD, 8-aminolevulinic acid dehydratase; BUN, blood urea nitrogen.
aALAD status: ALAD 1-1 orALAD 1-2, 2-2.
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type with blood lead levels. Ifthe converse
were true, a bias toward the null hypothesis
ofno genotype effect would occur.
The results reported here avoid this
potential selection bias by screening indi-
viduals directly for blood and bone lead
concentrations. We have also focused on a
population likely to have had modest expo-
sure to lead, a situation more representa-
tive of current overall population expo-
sures. This allows the relationship between
genotype and blood lead levels at low doses
to be more fully investigated. Finally, we
have initiated investigations into the possi-
ble association of this genotype with bone
lead concentrations and certain indicators
oflead toxicity.
Overall, blood lead levels in the popu-
lation ofunion members studied here aver-
aged 7.78 (± 3.60) jig Pb/dl. These results
indicate that current lead exposures among
this group are generally low. It is impor-
tant to note, however, that the union
members studied here may not be repre-
sentative ofthe overall union membership,
which may be composed of a higher per-
centage ofindividuals at risk for on-the-job
lead exposure. Many of our subjects were
full-time union representatives who had
not been actively working at construction
sites for several years (29).
Our results indicate that the ALAD-2
genotype is not a significant determinant
of blood lead concentrations among indi-
viduals exposed at relatively low levels.
Blood lead concentrations were essentially
identical between the ALAD genotypes
(Table 2) in this population. This suggests
that the association observed at higher
blood lead levels may not pertain to the
low-level exposure situation. The higher
level effect could be mechanistically depen-
dent on the kinetics oflead uptake and sat-
uration ofbinding to other blood proteins.
For example, some forms of hemoglobin
bind lead with great affinity (33,34). The
effect of the variant ALAD protein may
therefore be significant only after satura-
tion of such hemoglobin-associated lead-
binding sites and could thus be evidenced
only transiently after exposure to high lev-
els oflead. A recent study ofoccupational-
ly exposed Koreans, screened directly on
the basis ofblood lead levels, also supports
this possiblity: ALAD-2 was overrepresent-
ed only among individuals with blood lead
levels greater than 40 jsg/dl (35).
Although blood lead concentrations
have been used extensively to determine
lead uptake, the utility of this measure-
ment is limited to relatively recent expo-
sures. Because the half-life of lead in the
blood is 28-36 days, blood lead concentra-
tions only provide a reliable measure of
exposures that have occurred over a period
of a few weeks (36). Estimates oflonger-
term lead exposures are better provided by
determinations of bone-lead concentra-
tions, which can be made usingX-ray fluo-
rescence techniques developed over the
past decade (37).
Even though the overall pharmacoki-
netic distribution of lead in the body is
complex, it is clear that bone tissue consti-
tutes the major long-term storage depot for
this metal (38). The concentration oflead
in bone thus provides an integrated esti-
mate of exposures that have occurred over
a much longer period and are oftoxicolog-
ical concern, as these stores can be mobi-
lized, leading to continued systemic expo-
sures long after environmental exposures
have ceased (38). Bone serves as a long-
lived sink for up to 95% oftotal body bur-
dens oflead in adults (1).
Differences in lead accumulation in
various bone types has been noted. Patella
lead concentration values often differ from
those observed in the tibia (30-32). The
cortical bone ofthe tibia represents a long-
term storage depot which would be expect-
ed to exhibit a half-life for lead in excess of
a decade. In contrast, the more dynamic
trabecular bone of the patella exhibits a
shorter half-life. The precise mechanism
accounting for this difference is not
known, but is likely to be a function ofdif-
ferences in blood perfusion, rates of bone
turnover, and specific structural and com-
positional aspects ofthe bone matrix.
The cumulative nature of bone lead
concentrations and the expected differ-
ences in partitioning between patella and
tibia bone suggest that lead concentrations
in these two depots could provide a sensi-
tive indicator of genotype-related differ-
ences in the overall pharmacokinetics of
lead. Lead concentrations in these com-
partments were therefore determined for a
subset ofthose participating in this study.
The observed difference between patel-
la and tibia bone lead concentrations
between genotypes (Table 2) suggests that
ALAD status may modify the way in
which lead partitions between these bone
depots. Cortical bone concentrations will
better reflect earlier periods of potentially
higher lead exposure in this population.
The noted differences between cortical and
trabecular bone lead levels would be con-
sistent with a reduction in lead uptake into
long-term cortical bone storage sites, per-
haps via enhanced binding to ALAD-2
peripherally during periods of elevated
occupational exposure to lead. That is, the
variant ALAD-2 protein may effectively
increase the blood and soft tissue (e.g.,
spleen and kidney) compartment half-lives
oflead, decreasing partitioning to the cor-
tical bone compartment. This would be
expected to increase the cumulative expo-
sure to trabecular bone such as the patella.
Such a change in the distribution of lead
could also influence the partitioning of
lead to other tissues as well, potentially
leading to complex relationships between
genotype and toxicity. For example,
ALAD-2 may serve to sequester lead in a
form that is inaccessible to certain organs
such as the central nervous system. That
this may be the case is suggested by a
recent follow-up study of 72 adolescents
where all 5 individuals carrying ALAD-2
performed better on a battery ofneuropsy-
chological tests compared to those
homozygous forALAD-1 (39). In contrast,
decreased partitioning to long-term bone
storage could simultaneously increase the
cumulative delivery of lead to other organ
systems where the bound lead might be
more toxicologically available, perhaps due
to cellular processing such as might occur
during tubular transport in the kidney.
This could well exacerbate lead toxicity at
some sites.
Indeed, our results do suggest that low-
level blood lead concentrations may be
associated with subclinical kidney effects
(as evidenced by an increase in BUN val-
ues) and that ALAD-2 may contribute to
this. In logistic regression models with
BUN as the dependent variable and age,
ALAD status, and blood lead concentra-
tions as the independent variables, blood
lead concentration was significantly associ-
ated with BUN values (p = 0.01). Lead-
induced renal toxicity has been well estab-
lished in humans at relatively high blood
lead concentrations (6-9,40-43) and has
been suggested to occur at more modest
levels as well (44-46). Manifestations of
acute lead-induced kidney toxicity primari-
ly involve damage to the kidney tubules
with appearance of nuclear inclusion bod-
ies, overt dysfunction, decreased uric acid
excretion, and cytomegaly ofthe epithelial
cells of the proximal tubules (38).
Although many ofthese effects are consid-
ered reversible, prolonged or repetitive
exposure to lead may result in cumulative
kidney damage with potential incremental
loss function via progressive interstitial
fibrosis (6).
In workers with average blood lead lev-
els in excess of 80 jsg/dl, creatinine clear-
ance has been reported to be reduced (41).
BUN and serum uric acid levels were also
found to be elevated significantly in work-
ers with blood lead concentrations of72 (±
17) ug Pb/dl (40). In another study, sub-
clinical kidney damage was detected
through an association between blood lead
and N-acetyl-D-glucosaminidase, a sensitive
lysosomal marker of tubular cell toxicity.
Blood urea nitrogen, uric acid, and creati-
nine levels were, however, all within normal
ranges in this study (42). Aweak but statis-
tically significant association between blood
Volume 103, Number3, March 1995 251lead levels and BUN and serum creatinine
among 209 Japanese workers, only 5 of
whom exceeded 60 jig Pb/dl, has also been
reported (44), suggesting that lead-associat-
ed effects on these parameters may occur at
more modest blood lead levels. Finally, two
recent epidemiological studies have also
reported a dose-response relationship
between relatively low levels of lead in
blood (5-25 pg/dl) and decreased creati-
nine clearance (45,46).
Current blood lead levels may not pro-
vide an adequate dosimeter with respect to
kidney toxicity. Even short-term, high-level
lead exposures could hypothetically con-
tribute to clinical or subclinical effects
many years after exposure, even if the
effects appear to have reversed. Repair of
toxicant-induced kidney damage is unlikely
to perfectly restore the damaged tissues and
may thus lead to a permanent decrement in
the functional reserve capacity. Incremental
loss of kidney function resulting via other
mechanisms such as the normal aging
process and exposures to other renal toxins
could lead to functional insufficiencies that
might otherwise not have developed. Such
a mechanism may be involved in the lead-
associated BUN elevation observed here, in
effect preserving a rank order of effects
attributable to earlier higher-level lead
exposures. Alternatively, these results may
be indicative of low-level lead effects on
kidney function. Such effects have been
suggested in other recent studies (42-45).
Our results also suggest a potential
ALAD-2 relationship with lead-associated
renal effects. Elevated levels of BUN, uric
acid, and creatinine were all observed
among ALAD-2 versus ALAD-1 individu-
als in this population. Considered in isola-
tion, the association with BUN was statis-
tically significant (p = 0.03), but when
modeled, including other potentially sig-
nificant parameters, the associations
between genotype and BUN and uric acid
remained of borderline statistical signifi-
cance (p = 0.06 andp = 0.07, respectively).
Although ALAD-2 status could potentially
influence kidney function via a mechanism
independent of lead, these results are con-
sistent with the potential ALAD effects on
lead distribution discussed earlier. A
decrease in the relative distribution oflead
to long-term bone stores, even ifrestricted
to intermittent periods of high-level lead
exposure, where ALAD-2-blood lead asso-
ciations have been observed, would be like-
ly to increase the cumulative amount of
lead accessible to the kidney, potentially
exacerbating toxicity at this target organ.
As ALAD-2 is predominantly associated
with blood lead concentrations in excess of
30 jig/dI, such kidney effects would be
anticipated to be more pronounced among
those experiencing higher-level exposures.
In conclusion, the observed differences
in bone lead concentrations between the
tibia and patella are suggestive ofpotential
ALAD-2-associated pharmacokinetic
effects, perhaps due to a greater affinity of
the variant protein for lead. Such a differ-
ence may be of toxicological importance;
depending on the target organ ALAD-2
could protect against ultimate toxicity
(e.g., central nervous system effects) or
enhance toxicity (e.g., renal effects) due to
altered partitioning and availability of
complexed lead. Our results support this
possibility, suggesting that subclinical lead-
associated kidney dysfunction is associated
with relatively low current blood lead con-
centrations and that the ALAD-2 genotype
may be an additional modifier of this
effect. Further follow-up of these issues
among populations exposed to lead at
higher levels, where ALAD-2 effects on
blood lead levels have been noted, are
needed to confirm these observations.
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